WOLFE RESEARCH HEALTHCARE CONFERENCE 2026 - MORPHOSYS AG

Financial Performance:

• The core business, X-Jacify, grew over 30% year-over-year in Q3.
• Current X-Jacify revenue is projected to reach at least $3–$4 billion by 2030.
• The company holds approximately $4 billion on its balance sheet, expected to grow to $6 billion if unutilized for business development.
• Management anticipates a future top-quartile growth rate of 10–15% post-2029, driven by the pipeline.
• Non-Jacify hematologic products (Tibso, Monjuvi, Zion) are noted as a sizable business in their third year of launch with good trajectories, though subject to growth moderation.
• A single asset (Povacitinib) is estimated to potentially exceed $1 billion in annual sales without "heroic mathematical assumptions."

Guidance and Future Outlook:

• Long-term framework targets a post-2029 company capable of 10–15% top-line growth, combining a $3–4B core with an unadjusted $8–10B pipeline value.
• Povacitinib: Expected FDA approval in early 2027; aims to secure formulary coverage for 80–90% of plans by year-end.
• XR Conversion: Projected to land between 10% and 30% (midpoint 15%) by transitioning patients from X-Jacify; requires 50 basis points of monthly conversion for the next 26 months.
• 989 (Claris): Pivotal trial for first-line MF expected to launch in the first half of 2027; study design (type, arms, endpoint) to be finalized early 2027 pending FDA feedback and ASH data.
• 798 (Next-Gen Claris): Pivotal trials anticipated to begin in 2028, with preclinical data release expected late 2027; projected half-life of ~50 days allowing for less frequent dosing (sub-Q pre-filled syringe).
• G12D (Pancreatic Cancer): Pivotal trial for combination with chemotherapy to begin; data on combination with PRMT5 inhibitors (BMS partnership) and PARP inhibitors to emerge.
• G12D (Colorectal): Pivotal trial in third-line setting (prior BEV exposure) launching soon; decision on first-line partner (Cetuximab vs. Ripedacentamab) expected in 2027.
• TGF-beta/PD-1: Phase 3 study for MSS colorectal cancer enrolling ahead of schedule; PFS data expected in the first half of 2027.

Business Segments and Product Lines:

• Core Business (Dermatology): Focus on Povacitinib (oral multi-cytokine inhibitor) for Hidradenitis Suppurativa (HS), Prurigo Nodularis (PN), and Vitiligo; leveraging existing franchise of topical Opsalora to create a sequencing strategy.
• Core Business (Hematology): X-Jacify (JAK inhibitor) transition to XR; Monjuvi (Tibso) growth driven by potential frontline DLBCL indication (FDA action expected early 2027).
• Pipeline Assets:
  • 989: Lead CALR antibody; data on JAK-FI-eligible frontline MF patients to be presented at ASH; second-line JAK-ineligible data already shows directionally positive results.
  • 798: Next-generation CALR antibody with improved potency, half-life, and sub-Q delivery; designed to replace 989 post-approval.
  • G12D Inhibitor: Focus on multiple combinations in pancreatic cancer (chemo, PRMT5, PARP, EGFR) and colorectal cancer (Arbitrax, Cetuximab/Ripedacentamab).
  • TGF-beta/PD-1 Bispecific: High response rates (83% in PDL-1 positive patients with liver mets) in MSS colorectal cancer; deemed an "outlier opportunity" requiring further de-risking.

Market and Competitive Landscape:

• HS/PN: Povacitinib is positioned as the first oral multi-cytokine inhibitor approved by FDA; competition from IL-17s and biosimilars (Ymir) acknowledged but viewed as non-mutually exclusive in a large market.
• DLBCL: Monjuvi faces competition from Epkinley and Polivy in the frontline setting; a modest share gain could double the product's size.
• Pancreatic Cancer: Highly competitive; strategy involves offering multiple combination options rather than a single molecule.
• Colorectal: Landscape dominated by Lonsurf, Bev, Fingol, Regorafenib; G12D data (PFS ~7.2 months with Arbitrax) viewed as competitive.
• Market Expansion: Competition failures by other firms (HS, Prurigo) viewed as positive for validating market opportunity and potential for Insight to gain share.

Risks and Challenges:

• Execution Risk: Primary focus is on executing product launches (Povacitinib, XR conversion) and advancing Phase 3 programs.
• Regulatory & Endpoint Uncertainty: Finalizing study design for 989 first-line MF (type, arms, endpoints) and gaining FDA agreement on labels for Povacitinib remain key hurdles.
• Competition: Ongoing development by rivals in all therapeutic areas; "biology risk is not zero" but significantly reduced compared to the start of the year.
• PFS Data: TGF-beta program requires longer follow-up to confirm durability of response (PFS/survival) before full risk adjustment.
• Formulary Coverage: Success depends on securing appropriate price points and formulary positions against established IL-17s and biosimilars.

Management Commentary and Tone:

• Management tone is confident and execution-focused, emphasizing a structured framework with a clear path to value creation post-2029.
• Bill and Pablo expressed strong conviction in the pipeline's ability to drive recovery, particularly highlighting 989, G12D, and Latar Support as high value assets.
• Management acknowledged the necessity of waiting for final ASH data before making definitive claims on 989 efficacy in frontline MF but remains optimistic.
• They view the upcoming Povacitinib launch as a critical growth driver and a potential $1B+ asset, emphasizing the advantage of being first in HS and PN.

Analyst Questions and Answers:

• XR Conversion Rate: Analyst asked for 2-3 year extraction potential; Management explained 3% current share to 10-30% target requires ~50bps monthly conversion, aided by 80-90% formulary coverage by year-end.
• Monjuvi Growth: Asked if frontline DLBCL approval could be a top driver; Management confirmed it could double the product size given the evolved competition landscape.
• 989 Frontline Data: Analyst sought clarity on JAK-FI eligible data; Management confirmed the abstract is disseminated and emphasizes waiting for ASH presentation to confirm the path to approval.
• 798 Utility: Asked if preclinical data justifies 798 development; Management confirmed 798's superior potency (74x more potent against non-type 1 mutations) and half-life (~50 days) will make it "Best in Class" and obsolete 989 post-approval.
• G12D Partnerships: Analyst inquired about the strategy for pancreatic cancer partnerships; Management detailed collaborations with BMS (PRMT5) and others to offer multiple options based on molecular profiling.
• Povacitinib Pricing/Label: Asked about pricing strategy relative to label breadth; Management expects a price point within the current market corridor (middle of IL-17/Renvoc range) and noted that even partial access in pre-biologic settings creates a viable market.
• TGF-beta PFS Timing: Asked about confidence and timing for PFS separation; Management reiterated the need to wait for mature event-driven data in the first half of 2027 but remains "cautiously optimistic" regarding the high response rates.

Other Key Points:

• Business Development: The company maintains $4B (growing to $6B) cash on hand to acquire assets approved between 2029–2032, agnostic to therapeutic area (hematology, oncology, immunology).
• Product Franchise: The ability to market both topical (Opsalora) and oral (Povacitinib) therapies in HS creates a unique franchise advantage for physician sequencing strategies.
• Strategic Pivot: The company is transitioning from a single-product (X-Jacify) focus to a diversified growth engine driven by a robust pipeline and multiple new launches.
• Clinical Trial Speed: The TGF-beta Phase 3 study is enrolling "ahead of schedule," and the G12D third-line CRC study is in the process of launching to ensure fast market entry.
• Future Identity: Management asserts that Insight aims to be the "first" and "best-in-class" in CALR antibodies and G12D inhibitors, with 989 serving as the initial approved candidate followed by the superior 798.